-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, the state has issued a series of documents to promote the development of domestic innovative drugs, and gradually guide the development of China's pharmaceutical industry from large to strong, from imitation to innovation
.
The author has learned that in the rapid development of innovative drugs, news of many pharmaceutical companies' new drugs being launched or approved for clinical trials has also begun to spring up again and again
.
For example, this week, a number of new drugs from pharmaceutical companies have been approved for testing and listed on the market
.
On January 20, Sino Biopharmaceutical announced that Taibowei® (adalimumab injection) produced by its core company, Chia Tai Tianqing, was officially approved by the State Drug Administration for the use in rheumatoid arthritis, ankylosing spondylitis, Treatment of three major indications for psoriasis
.
It is understood that Humira, the original research drug of adalimumab, is known as the "global drug king" and contributed more than $20 billion in revenue to AbbVie last year
.
In this context, the industry believes that the listing of Taibowei is expected to leverage a potential market of 1 billion scale and benefit 20 million Chinese patients
.
Because of its higher safety compared with similar products, it can significantly reduce the incidence of extra-articular manifestations in patients
.
On January 18, Zhejiang Daoer Biotechnology Co.
, Ltd.
, a subsidiary of Huadong Pharmaceutical Holding Co.
, Ltd.
, received the "Notice of Approval of Drug Clinical Trials" (notice number: 2022LP00075) approved and issued by the National Medical Products Administration (NMPA)
.
The drug was approved by the Phase I clinical trial application of DR30303 for injection, which was filed by Doyle Biopharmaceuticals, and aims to evaluate the safety and tolerability of humanized Claudin18.
2 monoclonal antibody-DR30303 in the treatment of advanced solid tumors , pharmacokinetics and preliminary efficacy
.
It is known that Claudins are a class of integrin membrane proteins present in tight junctions of epithelium and endothelium, and are an important part of tight junctions
.
At present, its tumor-specific expression characteristics make it an important research and development target in the tumor field.
.
It is worth mentioning that there is currently no anti-Claudin18.
2 drug on the market in the world.
The approval notice for the clinical trial of DR30303 for injection was obtained this time, which is the first clinical trial application approved by Doyle, which will enrich the company's development in tumor therapy.
The product reserves in the field will increase the company's drug coverage in the field of innovative drugs and tumor disease treatment, and further enhance the company's comprehensive competitiveness
.
On January 17, the board of directors of Luye Pharmaceutical Group Co.
, Ltd.
announced that the marketing authorization application of the group's research product in the analgesic field, Oxycodone Naloxone Sustained-Release Tablets (LY021702), has also been accepted by the Center for Drug Evaluation of the State Drug Administration.
.
According to reports, LY021702 is the first high-tech oxycodone naloxone sustained-release tablet developed by a Chinese company.
It consists of a strong opioid agonist oxycodone hydrochloride and an opioid antagonist naloxone hydrochloride.
For moderate to severe chronic pain that cannot be effectively controlled by these drugs, the pain relief can last up to 12 hours, and it can effectively prevent the abuse of opioids and reduce gastrointestinal adverse reactions such as constipation caused by such drugs
.
The industry expects that Oxycodone Naloxone Sustained-Release Tablets will have good market potential in China, and can form a rich combination with Luye Pharma's anti-tumor products, and synergize with the existing resources and advantages in the tumor field to accelerate the promotion of Luye Pharma in the market.
layout and development in this field
.
.
The author has learned that in the rapid development of innovative drugs, news of many pharmaceutical companies' new drugs being launched or approved for clinical trials has also begun to spring up again and again
.
For example, this week, a number of new drugs from pharmaceutical companies have been approved for testing and listed on the market
.
On January 20, Sino Biopharmaceutical announced that Taibowei® (adalimumab injection) produced by its core company, Chia Tai Tianqing, was officially approved by the State Drug Administration for the use in rheumatoid arthritis, ankylosing spondylitis, Treatment of three major indications for psoriasis
.
It is understood that Humira, the original research drug of adalimumab, is known as the "global drug king" and contributed more than $20 billion in revenue to AbbVie last year
.
In this context, the industry believes that the listing of Taibowei is expected to leverage a potential market of 1 billion scale and benefit 20 million Chinese patients
.
Because of its higher safety compared with similar products, it can significantly reduce the incidence of extra-articular manifestations in patients
.
On January 18, Zhejiang Daoer Biotechnology Co.
, Ltd.
, a subsidiary of Huadong Pharmaceutical Holding Co.
, Ltd.
, received the "Notice of Approval of Drug Clinical Trials" (notice number: 2022LP00075) approved and issued by the National Medical Products Administration (NMPA)
.
The drug was approved by the Phase I clinical trial application of DR30303 for injection, which was filed by Doyle Biopharmaceuticals, and aims to evaluate the safety and tolerability of humanized Claudin18.
2 monoclonal antibody-DR30303 in the treatment of advanced solid tumors , pharmacokinetics and preliminary efficacy
.
It is known that Claudins are a class of integrin membrane proteins present in tight junctions of epithelium and endothelium, and are an important part of tight junctions
.
At present, its tumor-specific expression characteristics make it an important research and development target in the tumor field.
.
It is worth mentioning that there is currently no anti-Claudin18.
2 drug on the market in the world.
The approval notice for the clinical trial of DR30303 for injection was obtained this time, which is the first clinical trial application approved by Doyle, which will enrich the company's development in tumor therapy.
The product reserves in the field will increase the company's drug coverage in the field of innovative drugs and tumor disease treatment, and further enhance the company's comprehensive competitiveness
.
On January 17, the board of directors of Luye Pharmaceutical Group Co.
, Ltd.
announced that the marketing authorization application of the group's research product in the analgesic field, Oxycodone Naloxone Sustained-Release Tablets (LY021702), has also been accepted by the Center for Drug Evaluation of the State Drug Administration.
.
According to reports, LY021702 is the first high-tech oxycodone naloxone sustained-release tablet developed by a Chinese company.
It consists of a strong opioid agonist oxycodone hydrochloride and an opioid antagonist naloxone hydrochloride.
For moderate to severe chronic pain that cannot be effectively controlled by these drugs, the pain relief can last up to 12 hours, and it can effectively prevent the abuse of opioids and reduce gastrointestinal adverse reactions such as constipation caused by such drugs
.
The industry expects that Oxycodone Naloxone Sustained-Release Tablets will have good market potential in China, and can form a rich combination with Luye Pharma's anti-tumor products, and synergize with the existing resources and advantages in the tumor field to accelerate the promotion of Luye Pharma in the market.
layout and development in this field
.
